Abstract
Essential food workers experience an elevated risk of SARS-CoV-2 infection due to prolonged occupational exposures (e.g., frequent close contact, enclosed spaces) in food production and processing areas, shared transportation (car or bus), and employer-provided shared housing. The purpose of this study was to evaluate the impact of combined food industry interventions and vaccination on reducing the daily cumulative risk of SARS-CoV-2 infection for produce workers. Six linked quantitative microbial risk assessment models were developed in R to simulate daily scenarios experienced by a worker. Standard industry interventions (2 m physical distancing, handwashing, surface disinfection, universal masking, increased ventilation) and two-dose mRNA vaccinations (86–99% efficacy) were modeled individually and jointly to assess risk reductions. The infection risk for an indoor (0.802, 95% Uncertainty Interval [UI]: 0.472–0.984) and outdoor (0.483, 95% UI: 0.255–0.821) worker was reduced to 0.018 (93% reduction) and 0.060 (87.5% reduction) after implementation of combined industry interventions. Upon integration of these interventions with vaccination, the infection risk for indoor (0.001, 95% UI: 0.0001–0.005) and outdoor (0.004, 95% UI: 0.001–0.016) workers was reduced by ≥99.1%. Food workers face considerable risk of occupationally-acquired SARS-CoV-2 infection without interventions; however, consistent implementation of key infection control measures paired with vaccination effectively mitigates these risks.
Synopsis Bundled interventions, particularly if they include vaccination, produce significant reductions (>99%) in SARS-CoV-2 infection risk for essential food workers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially supported by the National Institutes of Health T32 grant (J.S.S., grant 2T32ES012870-16), the National Institute of Food and Agriculture at the U.S. Department of Agriculture (J.S.L. 2019-67017-29642; J.S.S., grant 2020-67034-31728), the National Institute General Medical Sciences (B.A.L R01 GM124280; B.A.L. R01 GM124280-03S1), the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health (E.T.S., T32AI138952), and Emory University and the Infectious Disease Across Scales Training Program (IDASTP) (E.T.S). The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health, or the U.S. Department of Agriculture.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The code developed and utilized throughout this analysis will be available through GitHub upon acceptance. All model parameters in the present work are contained in the manuscript.
